



amersham pharmacia biotech

To whom it may concern

**ON ANIMAL DERIVED MATERIALS IN THE MANUFACTURE OF  
17-0448-00<sup>1</sup> Cytodex™ 1 CELL CULTURE MEDIA**

The only use of animal derived components in the manufacture of Cytodex 1 chromatography media is in the manufacture of the base material raw dextran. The raw dextran is further processed to Dextran substances used also for medicinal products intended for injections. These medicinal products are and have been during many years been extensively used throughout the world.

**Animal-derived components in raw material in the production of Dextran substances**

The manufacturing of Dextran products, used for both clinical and technical applications, at Amersham Pharmacia Biotech AB involves the two production sites at Staffanstorp and Uppsala, Sweden.

The raw dextran is manufactured in a fermentation plant in Staffanstorp. A change in raw materials, comprising exclusion of the animal-derived components Trypton and porcine Liver Broth, in the inoculum substrate for production of inoculum culture for *Leuconostoc mesenteroides* has been introduced.

Another change, introduced concurrently, comprises the exclusion of all sources of animal origin when growing the bacterias for new working cell banks.

These changes have been validated to assure the consistency in process performance and product quality.

The only animal-derived component in the production of dextran that now remains is the skim-milk powder acting as cryo-protective agent at the lyophilisation of new cell banks. This skim-milk powder corresponds to level of less than 0.01 ppm in the final Dextran bulk substances.


The country of origin for this skim milk powder is USA. Milk is not a specified risk material as defined in Commission Decision 97/534/EC and is also unlikely to present any risk of contamination according to the European Pharmacopoeia monograph Products with risk of transmitting agents of animal spongiform Encephalopathies. The supplier intends to submit an application for a Certificate of Suitability no later than mid-September, 2000.

The changes in Staffanstorp were finally introduced in regular production of dextran in 1999 and are fully implemented for all batches of Dextran substances manufactured after 1 January 2000 (lot numbers > 281800).

\* ) The last two digits (-00) of the code number includes all the different packaging sizes.

Amersham Pharmacia Biotech AB tel +46 18 612 07 00  
Björkåsen 30 fax +46 18 612 12 00  
SE-751 84 Uppsala web site  
Sweden http://www.apb.com  
© 2000 Amersham Pharmacia Biotech

CAIF SA  
Dra. Bernarda Belay  
Co-Directora Técnica  
M.N. 15.148

  
CAIF  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Apoderada  
DNI 29378925





Dextran substances manufactures before January 1, 2000

For batches manufactured before January 1, 2000 was the above mentioned Tryptone and porcine Liver Broth used.


Tryptone is derived from milk. This source is not defined as specified risk material as defined in Commission Decision 97/534/EC

The tryptone used is, as of December 1996, manufactured from animals originating from countries free from bovine spongiform encephalopathy (BSE) as declared by the supplier. The countries of origin for the tryptone are Australia, New Zealand and USA. The supplier intends to submit an application for a Certificate of Suitability no later than mid-September, 2000.


Uppsala, Sweden, August 25, 2000

Lena Hellquist  
Regulatory Support

CAIF SA  
Dra. Bernarda Belay  
Co-Directora Técnica  
M.N. 15.146

  
CAIF  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Abogado  
CUI 2012023





GE Healthcare

### Animal Origin Statement

#### Regarding animal derived materials in Cytodex 1 surface microcarriers

---

Product:	Code Number:
Cytodex™ 1	17-0448-xx*
	*)-xx refers to all pack sizes

---

Based on the information below it is hereby stated that Cytodex 1 surface microcarriers do not contain, and is not derived from, specified risk material as defined in Regulation (EC) No 999/2001 (as amended).

One of the raw materials used for manufacture of Cytodex 1 microcarriers is dextran. This is the only raw material in the manufacture of the mentioned products containing animal derived materials.

#### After January 1, 2000

A change in raw materials, comprising exclusion of the animal-derived components tryptone and liver infusion broth, in the inoculum substrate for production of inoculum culture for *Leuconostoc mesenteroides* has been introduced. The only animal derived component in the production of dextran, after January 1, 2000, is the skim milk powder acting as a cryo-protective agent at the lyophilization of new cell banks. The country of origin for this skim milk powder is USA. More information on the skim milk is found below.

#### Before January 1, 2000

During the manufacture of one of the raw materials, native dextran, minute amounts of broth containing extracts from porcine liver (liver infusion broth) and bovine tryptone (Bacto Tryptone), are added to the stock culture of *Leuconostoc mesenteroides*.

Milk is the bovine component of the liver infusion broth. The countries of origin for the milk are Australia, New Zealand and USA. The porcine material is sourced from USA, Canada and Italy.

The countries of origin for the tryptone (Bacto Tryptone) are Australia, New Zealand and USA.

---

GE Healthcare Bio-Sciences AB  
 Björkgatan 30  
 SE-751 84 Uppsala  
 Sweden  
 T +46 (0)18 612 00 00  
 F +46 (0)18 612 12 00  
 Reg.No SE 55 61 08 1919

CAIF SA  
 Dra. Bernarda Belay  
 Co-Directora Técnica  
 Page No. 15.148

CAIF  
 Compañía Argentina de  
 Investigaciones Farmacológicas S.A.  
 Dra. María Bernarda Belay  
 Apoderada  
 CMT 29378925





GE Healthcare

Skim milk powder is used as cryo-protective agent at the lyophilization of new cell banks. This skim-milk powder corresponds to level of less than 0.01 ppm in the final Dextran bulk substances. The country of origin for this skim milk powder is USA.

The milk for liver infusion broth, tryptone and skim milk are sourced from animals "either deemed fit for human consumption or deemed healthy" as stated by the supplier, BD Diagnostics, USA. This information is in agreement with the European guideline "Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01- Rev 2)". Certificates of Suitability are not relevant for these raw materials.

It should be added that, during manufacture, dextran is subjected to several denaturing processes:

- fractionation at an ethanol concentration of 40% for a minimum of 32 hours
- treatment at pH 1.3 at 85°C for a minimum of 10 hours
- spray drying- inlet air temperature 230°C

Uppsala, Sweden, August 29, 2006

GE Healthcare Bio-Sciences AB  
Regulatory Affairs


Lena Hellquist  
Senior Regulatory Affairs Manager


GE Healthcare Bio-Sciences AB  
Björkgatan 30  
SE-751 84 Uppsala  
Sweden  
T +46 (0)18 612 00 00  
F + 46 (0)18 612 12 00  
Reg.No SE 55 61 08 1919



CAIF SA  
Dra. Bernarda Belay  
Co-Directora Técnica  
M.N. 15.148

Page 2 of 1

CAIF  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Aptorada  
CNI 25378925







**Module 3 – Quality**  
**3.2.S DRUG SUBSTANCE**  
Monovalent pools of inactivated  
poliomyelitis vaccine, NVI

Doc.:ENG-50963-Celite  
577.01

Replaces: -  
Date: 28 February 2008  
Drafted by: RvB  
Page 1 of 1


**Celite 577**

Specification	Requirement
Identity	
-	
Chemical tests	
Total ash	≤ 0.50 %
Particle size	≤ 40.0 µm
pH	< 7.0
Microbiological properties	
-	

CAIF SA  
Dra. Bernarda Belay  
Co-Directora Técnica  
M.N. 18.148

CAIF  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Apoderada  
DNI 29378925





### Module 3 – Quality

Inactivated poliomyelitis vaccine,  
suspension for injection

Doc.:ENG-51065-Guanine  
hydrochloride.01

Replaces: -  
Date: 28 February 2008  
Drafted by: RVB  
Page 1 of 1

**Guanine hydrochloride**

Specification	Requirement
Identity	
Melting point	≥ 300 °C
Chemical tests	
Total ash	≤ 0.05 %
Total impurities	≤ 2 %
Content	≥ 99.0 %
Microbiological properties	

CAIF SA  
 Dra. Bernarda Belay  
 Co-Directora Técnica  
 M.N. 15.145

CAIF  
 Compañía Argentina de  
 Investigaciones Farmacéuticas S.A.  
 Dra. María Bernarda Belay  
 Aposedada  
 DNI 29378925





The animals (Cynomolgus monkeys (Macaca fascicularis)) used for monkey kidney cell preparation were tested and complied according to the following tests:

<u>Specification</u>	<u>Requirement</u>
Antibodies to	
- Herpesvirus simiae (B virus)	negative
- SV40	negative
- Foamyvirus type 1, 2 and 3	negative
Tuberculosis (Mantoux reaction)	negative
Physical condition	no signs of illness

In a frequency of once per year, the monkeys were tested for the absence of antibodies against the agents mentioned in the table. Just prior to the kidney perfusion, these tests were repeated, with the exception of SIV.


<u>Specification</u>	<u>Requirement</u>	<u>Validity result</u>
Antibodies to:		
- SIV	negative	12 months
- Foamy	negative	14 days
- Herpes simplex virus*	negative	14 days
- SV 40	negative	14 days
- Polyoma	negative	14 days
M. tuberculosis (Mantoux test)	negative	14 days
Physical condition	no signs of illness	
Pathology	no abnormalities	

\* as indicator for HV simian B

CAIF SA  
 Dra. Bernarda Bejay  
 Co-Directora Técnica  
 M.N. 15.148

CAIF  
 Compañía Argentina de  
 Investigaciones Farmacéuticas S.A.  
 Dra. Bernarda Bejay  
 Apodada  
 DNI 2934975





The monkey kidney cells were tested and complied according to the following requirements:


**Control cell cultures:**

Test	Method	Requirement
Test for CPE and haemadsorbing viruses	According to Ph. Eur. 2.6.16. CPE is assessed by microscopical examination. Addition of guinea-pig red blood cells.	No evidence of CPE or haemadsorbing agents is found.
Extraneous agents	According to Ph. Eur. M-0214 Test in rabbit kidney cell cultures.	No evidence of Herpes-B virus or other adventitious agents is found
Extraneous agents	According to Ph. Eur. M-0214 Test in cercopithecus kidney cell cultures	No evidence of SV40 or other adventitious agents is found
Mycobacteria	According to Ph. Eur. 2.6.2 Inoculation in Loewenstein, 7H10 and Tween-albumin media.	No growth of mycobacteria

CAIF SA  
 Dra. Bernarda Belay  
 Co-Directora Técnica  
 M.N. 15.148

*(Handwritten signature)*  
 CAIF  
 Compañía Argentina de  
 Investigaciones Farmacéuticas S.A.  
 Dra. María Bernarda Belay  
 Aboderada  
 DNI 29378925





3.2.S.2.3 -- Control of Materials



Invitrogen Limited  
3 Fountain Drive  
Innovation Business Park  
Parsippany NJ 07054  
Tel: 0141 814 6100  
Fax: 0141 814 6158  
www.invitrogen.com

### CERTIFICATE OF ORIGIN STATEMENT

Product Description: Trypsin 1:250  
Catalogue Number: 27250

This is to certify that the above mentioned product has the following source and origin:

Source	Origin
Porcine Pancreas	USA/Canada
Lactose	USA

We can confirm that USA and Canada are considered to be free of BSE/TSE.


*Debbie Hamilton*


Debbie Hamilton  
Quality Systems

Registered No. 07307 Scotland

CAIF SA  
Dra. Bernarda Belay  
Co-Directora Técnica  
M.N. 15.148

CAIF  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Aprobada  
DNI 29376925





3.2.S.2.3 – Control of Materials



**Raw Material Technical Information**

Product: Trypsin 1:250

Raw Material Part #: 840-7072 (Used in all GIBCO brand Trypsin solutions)


Source: Porcine Pancreas

Country of Origin: US or Canada

Country of Manufacture: Canada

**Manufacturing Process:**

Flow chart of manufacturing process



Manufacturing notes:

- The bovine lactose used to adjust the activity of trypsin powder is of US origin. This lactose is refined from bovine milk and derived from healthy animals in the same conditions as milk collected for human consumption. No other ruminant materials are used during the processing.
- The raw powder Trypsin 1:250 is then irradiated at a minimum of 25 kGY. A certificate of irradiation accompanies each lot of Trypsin Invitrogen receives.

**Regulatory Information:**

The bovine lactose and trypsin itself are excluded from the scope of the Note for Guidance on "Minimizing the risk of transmitting animal Spongiform encephalopathy agents via human and veterinary medicinal products" (Revision February 2001, EMEA/410/01-Final).

**Additional Information:**

Pancreas Collection

Pork Pancreas glands are collected in USDA licensed pork slaughter plants under the inspection of USDA veterinarians. Pigs are subjected to ante- and post-mortem inspection, and glands are saved only from animals judged acceptable for human consumption.

CAIF SA  
 Dra. Bernarda Belay  
 Co-Directora Técnica  
 M.N. 15.148  
 CAIF  
 Compañía Argentina de  
 Investigaciones Farmacéuticas S.A.  
 Dra. María Bernarda Belay  
 Apoderada  
 DNI 29.178.925





HyClone New Zealand  
Omokoroa Farm  
441 Old Highway  
P.O. Box 658  
Tauranga, New Zealand

Product: **DONOR BOVINE SERUM**  
Collected and Processed in New Zealand  
Custom Filtered for NVI

Catalog#: **SH3A1248.01**

Manufacture Date: **OCT/2006**

Lot#: **DRK0265**

Expiration Date: **OCT/2011**

Filtration: **0.2 µm Sterile Filtered**

Total Batch Volume: **1034.7 L**

### CERTIFICATE OF ANALYSIS

Test/(Method)	Specification	Units	Results
Endotoxin (Limulus Amebocyte Lysate-Gel Clot, Current USP and EP)	≤ 5	EU/mL	<0.06
Haemoglobin (Spectrophotometric)	≤ 4	mg/dL	2
Sterility Testing (Ph. EUR. 2.6.1) (Current USP and EP)			
Bacteria and Fungi	No Growth		No Growth
Virus Testing (Full EMEA) Fluorescent Antibody			
Bluetongue	Not Detected		Not Detected
Bovine Adenovirus	Not Detected		Not Detected
Bovine Parvovirus	Not Detected		Not Detected
Bovine Respiratory Syncytial Virus	Not Detected		Not Detected
Bovine Viral Diarrhoea Virus	Not Detected		Not Detected
Bovine Leukemia Virus	Not Detected		Not Detected
Rabies	Not Detected		Not Detected
Reovirus	Not Detected		Not Detected
Cytopathogenic Agents - e.g. IBR	Not Detected		Not Detected
Haemadsorbing Agents - e.g. PT3	Not Detected		Not Detected
Bovine Virus Diarrhoea Virus (Pre-Irradiation)			
Interference/Comparative Titration	No Interference		No Interference
Bovine Virus Diarrhoea Virus (Post-Irradiation)			
Interference/Comparative Titration	No Interference		No Interference
Irradiation Dose	25-35 kGy		27,53 - 32,06
pH	For Information Only		8.02
Osmolality (Ph. Eur 2.2.35)	240-340	mOsm/kg	269

Page 1 of 2

Information available in: • Methods • Journals • Reagents • Serum • Media • PBS • Buffers

Phone: +64 7 546 0225  
Fax: +64 7 546 1296

Toll Free: 800-522-5353

Internet: www.hyclone.com  
Email: info@hyclone.com

CAIF SA  
Dra. Bernarda Belay  
Ingeniera Técnica

CAIF Page 1 of 12  
Compañía Argentina de  
Investigaciones Farmacéuticas S.A.  
Dra. María Bernarda Belay  
Apodada  
DN: 29373923





HyClone New Zealand  
 Omokoroa Farm  
 441 Old Highway  
 P.O. Box 668  
 Tauranga, New Zealand

Product: **DONOR BOVINE SERUM**  
**Collected and Processed in New Zealand**  
**Custom Filtered for NVI**

Catalog#: **SH3A1248.01**

Manufacture Date: **OCT/2006**

Lot#: **DRK0265**

Expiration Date: **OCT/2011**

Filtration: **0.2 µm Sterile Filtered**

Total Batch Volume: **1034.7 L**

### CERTIFICATE OF ANALYSIS

Test/(Method)	Specification	Units	Results
Total Protein	≥ 35	mg/mL	69
Albumin	For Information Only	g/dL	3.55
Alpha - 1 Globulin	For Information Only	g/dL	0.27
Alpha - 2 Globulin	For Information Only	g/dL	0.99
Beta Globulin	For Information Only	g/dL	1.55
Gamma Globulin	For Information Only	g/dL	0.74


The raw material used to produce this batch of serum has been sourced exclusively from clinically healthy cattle which were born and maintained in a country which is officially recognised as being free from Bovine Spongiform Encephalopathy (BSE), namely New Zealand

The raw material used was not derived from animals:

- Which have died on the farm, including newborn animals or foetuses.
- Which have been killed to eradicate epizootic diseases.
- Showing any clinical signs and/or lesions of contagious diseases for humans, or for reasons of residues, were declared unfit for human consumption.

The raw materials used were sourced from animals free from Tuberculosis, Leptospirosis, Brucellosis, Bluetongue and Bovine Leukemia Virus. The donor animals are screened regularly for these infectious agents unless the country of origin is declared to be free from these agents by the current OIE. The source herd is not vaccinated against these agents.

South Pacific Sera has been granted a Certificate of Suitability to the European Pharmacopoeia Monograph for New Zealand Sourced Donor Bovine Serum. The current certificate R1-CEP 2000-341 is included.

  
 Caroline Newcombe  
 QA/QC Manager

Page 2 of 2

Phone: + 64 7 548 0226  
 Fax: + 64 7 548 1295

Toll Free: 800-822-5355


Internet: www.hyclone.com  
 Email: info@hyclone.com

CAIF SA  
 María Belay

Co-Director  
 M.N. 15.148

CAIF  
 Compañía Argentina de  
 Investigaciones Farmacéuticas S.A.  
 Dra. María Berná Belay  
 APO. 146  
 DNI 29376925

Page 2 of 12





HyClone New Zealand  
 Omokoroa Farm  
 441 Old Highway  
 P.O. Box 858  
 Tauranga, New Zealand

Product: **DONOR BOVINE SERUM**  
**Collected and Processed in New Zealand**  
**Custom Filtered for NVI**

Catalog#: **SH3A1248.01**      Manufacture Date: **OCT/2006**  
 Lot#: **DRK0265**      Expiration Date: **OCT/2011**  
 Filtration: **0.2 µm Sterile Filtered**      Total Batch Volume: **1034.7 L**

### BIOCHEMICAL ASSAY

Test	Lot	Value
Alkaline Phosphatase	133	U/L
Blood Urea Nitrogen	10	mg/dL
Calcium	9.7	mg/dL
Chloride	98	mmol/L
Cholesterol	108	mg/dL
Creatinine	1.2	mg/dL
Glucose	38	mg/dL
Glutamic Oxaloacetic Transaminase (SGOT)	59	U/L
Glutamic Pyruvic Transaminase (SGPT)	61	U/L
Inorganic Phosphorus	6.5	mg/dL
Lactate Dehydrogenase (LDH)	2743	U/L
Potassium	4.5	mmol/L
Sodium	136	mmol/L
Specific Gravity	1.00372	g/mL
Total Bilirubin	<0.1	mg/dL

Product: 55 don't have a medical certificate - 1000 units - Serum (for medical) - FFS - 1000 units - 1000 units

Phone: + 64 7 546 0225  
 Fax: + 64 7 548 1295

Toll Free: 800-322-6355

Internet: www.hyclone.com  
 Email: info@hyclone.com

CAIF SA  
 Dra. Bernarda Belay  
 Jefa Técnica

CAIF  
 Compañía Argentina de  
 Investigaciones Farmacológicas S.A.  
 Dra. María Bernarda Belay  
 Apoderada  
 DNI 29376925

Page 3 of 12

